The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 3 briefings matching “statin”

Reset all filters

Infectious Disease

Infectious Disease Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

INFECTIOUS DISEASE · PHASE III

Imipenem-cilastatin-funobactam versus imipenem-cilastatin-relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial

Imipenem-cilastatin-funobactam is statistically non-inferior to imipenem-cilastatin-relebactam for 14-day all-cause risk of death in patients with HABP and VABP with a favourable safety profile. New antibiotics are urgently needed for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Infectious DiseasesNov 4, 2026

INFECTIOUS DISEASE · CLINICAL PRACTICE

Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration

These findings suggest that ECs have gut microbiota resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut microbiota diversity in PWH. There was a significant change in beta diversity after aspirin administration, but no difference in microbiota after atorvastatin.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious DiseasesOct 9, 2026

INFECTIOUS DISEASE · REAL-WORLD COHORT

When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside

Such reporting can strengthen stewardship, surveillance, and patient-level decisions across tertiary, routine, and resource-constrained settings, without overstating what MICs can predict alone at the bedside. The microbiologist makes the MIC interpretable by defining organism, method, interpretive threshold, confidence, and need for confirmation; the clinician makes it clinically useful by integrating exposure, site, source control, toxicity, interactions, and clinical trajectory.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Infectious DiseasesOct 8, 2026

Interactive Fact Check